Compare
Vaxcyte, Inc. vs Bio-Techne Corp vs Qiagen N.V. vs Immunocore Holdings plc
| Latest fiscal year | Vaxcyte, Inc. PCVX | Bio-Techne Corp TECH | Qiagen N.V. QGEN | Immunocore Holdings plc IMCR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $1.22B | $2.09B | $400.02M |
| Revenue growth (YoY) | n/a | -0.4% | +5.7% | +29.0% |
| Gross margin | n/a | 65.8% | 62.2% | n/a |
| Operating margin | n/a | 20.7% | 22.3% | -11.3% |
| Net margin | n/a | 15.0% | 20.3% | -8.9% |
| Net income | -$766.63M | $181.86M | $424.88M | -$35.51M |
| EPS (Diluted) | -$5.63 | $1.16 | $1.94 | -$0.71 |
| Operating cash flow | -$655.58M | $292.07M | $654.33M | -$10.71M |
| Free cash flow | -$669.29M | $263.22M | $453.28M | -$15.05M |
| Cash & equivalents | $173.96M | $264.71M | $839.00M | $467.71M |
| Total assets | $3.00B | $2.59B | $6.28B | $1.07B |
| Total liabilities | $317.21M | n/a | n/a | $686.24M |
| Shareholders' equity | $2.69B | $2.11B | $3.78B | $381.03M |
| Return on year-end equity | -28.5% | 8.6% | 11.2% | -9.3% |
| Shares outstanding | 131.06M | 156.10M | n/a | 50.69M |
Revenue, most recent five fiscal years
| Fiscal year | Vaxcyte, Inc. | Bio-Techne Corp | Qiagen N.V. | Immunocore Holdings plc |
|---|---|---|---|---|
| Latest | n/a | $1.22B Ended 2026-06-30 | $2.09B Ended 2025-12-31 | $400.02M Ended 2025-12-31 |
| 1 year earlier | n/a | $1.22B Ended 2025-06-30 | $1.98B Ended 2024-12-31 | $310.20M Ended 2024-12-31 |
| 2 years earlier | n/a | $1.16B Ended 2024-06-30 | $1.97B Ended 2023-12-31 | $249.43M Ended 2023-12-31 |
| 3 years earlier | n/a | $1.14B Ended 2023-06-30 | $2.14B Ended 2022-12-31 | $174.36M Ended 2022-12-31 |
| 4 years earlier | n/a | $1.11B Ended 2022-06-30 | $2.25B Ended 2021-12-31 | $36.48M Ended 2021-12-31 |